Home / Deep Research / IgG4-Related Sclerosing Cholangitis

IgG4-Related Sclerosing Cholangitis

1. Disease Information

2026-05-06
Falcon MONDO:0018645 Model: Edison Scientific Literature 41 citations

1. Disease Information

1.1 What is the disease?

IgG4-SC is an immune-mediated chronic fibroinflammatory cholangitis characterized by bile-duct strictures and wall thickening, lymphoplasmacytic inflammation rich in IgG4-positive plasma cells, fibrosis, and a typically strong response to glucocorticoids. It is widely recognized as the biliary manifestation of IgG4-RD and frequently occurs with type 1 AIP. (kamisawa2019clinicalpracticeguidelines pages 2-4, ali2020thelongtermoutcomes pages 1-2, beuers2025igg4relatedcholangitis pages 1-3)

1.2 Key identifiers (OMIM, Orphanet, ICD-10/ICD-11, MeSH, MONDO)

  • ICD-10 / ICD-11 / MeSH / MONDO / Orphanet / OMIM: Not explicitly provided in the full-text evidence retrievable in this run; therefore these IDs cannot be asserted here without external ontology lookups. (hegade2019diagnosisandmanagement pages 1-2)

1.3 Synonyms and alternative names

1.4 Evidence source type (individual vs aggregated)

The report is derived from aggregated disease-level resources (clinical practice guidelines, multicenter diagnostic validation, and large cohorts) and selected trial registry entries. (kamisawa2019clinicalpracticeguidelines pages 6-7, ali2020thelongtermoutcomes pages 1-2, naitoh2026multicentervalidationstudy pages 1-2, NCT02616705 chunk 1)

2. Etiology

2.1 Disease causal factors (mechanistic)

IgG4-SC is best understood as an immune-mediated, antigen-driven fibroinflammatory disease in genetically susceptible individuals. Mechanistically, a dysregulated adaptive immune response (including Th2/Treg-skewed cytokine milieu) promotes B-cell activation and expansion of IgG4+ B cells/plasmablasts, contributing to chronic inflammation and progressive fibrosis. (ren2026igg4relatedsclerosingcholangitis pages 2-3, smit2016newthoughtson pages 12-14)

2.2 Risk factors

Demographic

Clinical

Environmental/occupational (evidence limited)

Occupational antigen exposure has been proposed in some cohorts (e.g., high rates of “blue-collar” work reported in certain populations), but robust causal data for IgG4-SC specifically were not available in the retrieved excerpts. (tanaka2019igg4relatedsclerosingcholangitis pages 1-2)

2.3 Protective factors

No protective genetic or environmental factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

Not established in the retrieved evidence. However, the conceptual model emphasizes genetic susceptibility and environmental triggers acting together. (ren2026igg4relatedsclerosingcholangitis pages 2-3)

3. Phenotypes

3.1 Core clinical phenotypes (with suggested HPO terms)

Common presentations and laboratory abnormalities include:

  1. Obstructive jaundice (HPO: Jaundice HP:0000952) (herta2025managementofigg4related pages 1-2, kamisawa2019clinicalpracticeguidelines pages 6-7)
  2. Upper abdominal pain/discomfort (HPO: Abdominal pain HP:0002027) (herta2025managementofigg4related pages 1-2, ali2020thelongtermoutcomes pages 2-4)
  3. Cholestatic liver enzyme elevation (HPO: Elevated alkaline phosphatase HP:0003155; Elevated gamma-glutamyltransferase HP:0031304) (ali2020thelongtermoutcomes pages 2-4)
  4. Biliary strictures (HPO: Bile duct stenosis HP:0031783 [term mapping may vary]) (kamisawa2019clinicalpracticeguidelines pages 2-4, naitoh2026multicentervalidationstudy pages 2-2)
  5. Weight loss (HPO: Weight loss HP:0001824)—also contributes to malignancy mimicry (herta2025managementofigg4related pages 1-2)

Phenotype characteristics: * Typical onset: adult/older adult (no pediatric cases reported in Japan guideline summary). (kamisawa2019clinicalpracticeguidelines pages 6-7) * Variable severity; a meaningful fraction may be asymptomatic at diagnosis (28%) in Japanese experience. (kamisawa2019clinicalpracticeguidelines pages 6-7)

3.2 Quality of life impact

Specific QoL instruments (SF-36/EQ-5D/PROMIS) were not reported in the retrieved evidence for IgG4-SC.

4. Genetic/Molecular Information

4.1 Causal genes

No monogenic causal gene for IgG4-SC was identified in the retrieved evidence; the condition is best supported as complex immune-mediated with susceptibility signals rather than Mendelian inheritance. (ren2026igg4relatedsclerosingcholangitis pages 2-3)

4.2 Susceptibility genetics / loci (strength: moderate)

  • Whole-blood methylation/genotyping study in IgG4-SC showed a strong HLA-region signal in meQTL analyses, implicating loci including HLA-DQB2, HLA-DPA1, HLA-F, HLA-DRA in shaping methylation patterns. (noble2025epigeneticageacceleration pages 1-2)
  • Related PSC research demonstrates that elevated IgG4 in PSC associates with specific HLA haplotypes (lower HLA-B08; higher HLA-B07 and DRB1*15), underscoring shared immunogenetic architecture relevant for differential diagnosis contexts. (berntsen2015associationbetweenhla pages 1-1)

4.3 Epigenetic information (recent “omics”)

Noble et al. profiled whole-blood DNA methylation in 47 IgG4-SC, 65 PSC, 64 UC, 88 controls and found: * 19 significant methylation differences vs controls in IgG4-SC (38 in PSC). * Epigenetic age acceleration in IgG4-SC (not PSC/UC). * Dysregulated methylation in inflammatory genes including IFNAR1, TXK, HERC6, etc. (noble2025epigeneticageacceleration pages 1-2)

4.4 Chromosomal abnormalities

Not reported.

5. Environmental Information

No specific toxins, lifestyle exposures, or infectious triggers were established in the retrieved evidence for IgG4-SC. (ren2026igg4relatedsclerosingcholangitis pages 2-3)

6. Mechanism / Pathophysiology

6.1 Current mechanistic model (causal chain)

  1. Predisposition/trigger: genetic susceptibility and possible environmental triggers (incompletely defined). (ren2026igg4relatedsclerosingcholangitis pages 2-3)
  2. Immune activation: Th2/Treg-skewed responses with B-cell activation; oligoclonal expansion of IgG4+ plasmablasts. (ren2026igg4relatedsclerosingcholangitis pages 2-3, smit2016newthoughtson pages 12-14)
  3. Tissue inflammation: lymphoplasmacytic infiltrate rich in IgG4+ plasma cells; formation of fibroinflammatory lesions causing biliary wall thickening/strictures. (herta2025managementofigg4related pages 1-2, smit2016newthoughtson pages 6-8)
  4. Fibrosis and remodeling: storiform fibrosis and profibrotic cytokine signaling (e.g., TGF-β) contribute to progressive stricturing and potential secondary biliary cirrhosis in a minority. (ren2026igg4relatedsclerosingcholangitis pages 2-3, ali2020thelongtermoutcomes pages 7-8)

6.2 Key immune cells (suggested CL terms)

6.3 Key biological processes (suggested GO terms)

6.4 Histopathology (defining features)

Diagnostic histology requires combinations of: * Dense lymphoplasmacytic infiltrate * Storiform fibrosis * Obliterative phlebitis with IgG4+ plasma cell thresholds of >10/HPF (biopsy) or >50/HPF (resection) and IgG4+/IgG+ ratio >0.4. (herta2025managementofigg4related pages 1-2, smit2016newthoughtson pages 6-8)

7. Anatomical Structures Affected

7.1 Organ/tissue level (suggested UBERON terms)

7.2 Localization patterns

IgG4-SC has diverse cholangiographic patterns; Japanese guidance describes four cholangiographic types, with national survey frequencies: type 1 64%, type 2a 5%, type 2b 8%, type 3 10%, type 4 10%. (kamisawa2019clinicalpracticeguidelines pages 2-4)

8. Temporal Development

8.1 Onset

Typically adult/older adult onset; Japan guideline reports no pediatric/adolescent cases. (kamisawa2019clinicalpracticeguidelines pages 6-7)

8.2 Progression/course

Course is often responsive to steroids but relapsing. Reviews cite relapse rates commonly 30–50% despite high initial response, and post-steroid relapse rates around 40–50% in cited studies. (ren2026igg4relatedsclerosingcholangitis pages 2-3, hegade2019diagnosisandmanagement pages 4-5)

9. Inheritance and Population

9.1 Epidemiology

Japan guideline estimates prevalence 2.0 per 100,000 (~2,500 patients) and extrapolated prevalence/incidence based on AIP data of 1.8 per 100,000 and 0.5 per 100,000, respectively. (kamisawa2019clinicalpracticeguidelines pages 6-7)

9.2 Population demographics

9.3 Inheritance pattern

No Mendelian inheritance is established; evidence supports a complex immune-mediated condition with genetic susceptibility signals. (ren2026igg4relatedsclerosingcholangitis pages 2-3)

10. Diagnostics

10.1 Clinical criteria and diagnostic frameworks

HISORt

HISORt integrates Histology, Imaging, Serology, Other organ involvement, and Response to therapy; it is emphasized because no single pathognomonic test exists and mimics are common. (herta2025managementofigg4related pages 1-2, smit2016newthoughtson pages 6-8)

Japanese clinical diagnostic criteria (2012; revision 2020)

The IgG4-SC2020 criteria include six domains: bile-duct narrowing, bile-duct wall thickening, serology, pathology, other-organ involvement, and response to treatment. (naitoh2026multicentervalidationstudy pages 2-2)

A multicenter validation (Japan; 1,034 IgG4-SC and 447 mimickers) found sensitivity 99.0% (2020) vs 89.1% (2012) while maintaining specificity 100% vs pancreatic cancer and cholangiocarcinoma, and 97.5% vs PSC (2020). (naitoh2026multicentervalidationstudy pages 1-2)

10.2 Key diagnostic thresholds and pitfalls

10.3 Differential diagnosis

Primary mimickers: * Cholangiocarcinoma (CCA) * Primary sclerosing cholangitis (PSC) The need to differentiate these is a central theme across guidelines and diagnostic reviews. (herta2025managementofigg4related pages 1-2, kamisawa2019clinicalpracticeguidelines pages 2-4, ren2026igg4relatedsclerosingcholangitis pages 2-3)

10.4 Biomarker development and real-world diagnostic implementation

  • ClinicalTrials.gov observational cohort NCT02616705 assessed bile IgG4 concentration as a diagnostic biomarker to distinguish IgG4-SC from PSC/CCA and other strictures (enrollment 511; completed 2019-09-30). (NCT02616705 chunk 1)

11. Outcome / Prognosis

11.1 Cohort outcomes

In the Mayo Clinic IgG4-SC cohort (n=89; 1999–2018), hepatobiliary adverse events occurred less frequently than in matched PSC patients: 15.6 vs 52.6 events/1000 person-years, with 10-year hepatobiliary event probability 11% vs 45%. Ten-year survival was 79% in IgG4-SC vs 68% in PSC (trend). (ali2020thelongtermoutcomes pages 1-2)

11.2 Cirrhosis and cholangiocarcinoma risk

The Mayo experience excerpt reports progression to cirrhosis in ~5.2–7.5% across reports and an estimated lifetime CCA risk of 3.4% in that cohort; CCA cases occurred 1.5–5.8 years after IgG4-SC diagnosis in that cohort. (ali2020thelongtermoutcomes pages 7-8)

11.3 Prognostic factors

Relapse risk is highlighted as substantial; in pancreaticobiliary IgG4-RD cohorts, relapse risk relates to factors such as younger age and higher post-induction disease activity indices (IgG4-RI) and alkaline phosphatase in one rituximab maintenance analysis. (majumder2018rituximabmaintenancetherapy pages 1-2)

12. Treatment

12.1 First-line: glucocorticoids

Steroids are first-line once diagnosis is confirmed.

Evidence-supported regimens and relapse statistics: * Expert centers use prednisolone 0.5 mg/kg (30–40 mg/day) for 2–4 weeks, then taper by 5 mg steps. (hegade2019diagnosisandmanagement pages 5-6) * Reported post-steroid relapse rates include 40% after an 11-week course and 50% at median 4.6 months after stopping first course in cited studies. (hegade2019diagnosisandmanagement pages 4-5)

MAXO suggestions: * MAXO: glucocorticoid therapy (term label varies by MAXO release).

12.2 Steroid-sparing immunomodulators

Steroid-sparing regimens listed in hepatobiliary IgG4-RD review include: * Azathioprine 2 mg/kg daily * Mycophenolate mofetil 750–1,000 mg BID * Methotrexate 10–25 mg weekly (+ folate) * Tacrolimus (target level 4–11 ng/mL) * Rituximab 1,000 mg at week 0 and week 2 (B-cell depletion) (culver2016igg4relatedhepatobiliarydisease pages 7-8)

MAXO suggestions: * MAXO: immunosuppressive agent administration.

12.3 B-cell depletion: rituximab (real-world implementation)

In pancreaticobiliary IgG4-RD cohorts: * 6-month steroid-free remission after rituximab: 86%. * 3-year relapse/event rate 45% (induction only) vs 11% (maintenance) (P=.034). * Clinically significant infections occurred in 6/43, largely during maintenance. (majumder2018rituximabmaintenancetherapy pages 1-2)

MAXO suggestions: * MAXO: rituximab therapy / B cell depletion therapy.

12.4 Endoscopic management of biliary strictures (real-world)

In a 69-patient IgG4-SC cohort treated with corticosteroids: * 40.6% underwent endoscopic biliary drainage (EBD) before steroids. * Planned stent removal: 84.6% of removals occurred within 1 month after steroids with no early recurrence. * Spontaneous stent dislodgement occurred in 35.7% after steroids; 70% of dislodgements occurred between 2 weeks and 2 months. * Bile-duct stones developed in 4.3% (all in EBD group), and none in steroid-only group (p=0.032). (miyazawa2020managementofbiliary pages 1-2)

Supporting visual tables are available from the paper’s extracted tables. (miyazawa2020managementofbiliary media 3f18bf73, miyazawa2020managementofbiliary media a80fe471, miyazawa2020managementofbiliary media 500893f9)

MAXO suggestions: * MAXO: endoscopic biliary stenting; endoscopic stent removal.

12.5 Emerging/novel therapies

Recent reviews note emerging B-cell–targeting approaches (e.g., anti-CD19), but IgG4-SC–specific primary efficacy data were not retrievable in this run. (herta2025managementofigg4related pages 1-2)

13. Prevention

No established primary prevention strategies are described in the retrieved evidence. Secondary/tertiary prevention centers on early diagnosis to avoid unnecessary surgery and prevent fibrotic complications, plus surveillance for relapse and biliary complications. (herta2025managementofigg4related pages 1-2)

14. Other Species / Natural Disease

No naturally occurring animal disease or zoonotic aspects were identified in the retrieved evidence.

15. Model Organisms

No specific animal models or in vitro models of IgG4-SC were identified in the retrieved evidence.

Recent developments and latest research emphasis (2023–2025 within retrieved sources)

  • Diagnostic criteria modernization: IgG4-SC2020 criteria show markedly improved sensitivity vs 2012 while maintaining high specificity in a large Japanese multicenter validation (published 2026, but directly relevant to the “current understanding”). (naitoh2026multicentervalidationstudy pages 1-2)
  • Epigenetic/omics: First whole-blood methylation study in IgG4-SC identifies disease-specific methylation differences and epigenetic age acceleration; HLA-region meQTL signals suggest genotype–methylome relationships. (noble2025epigeneticageacceleration pages 1-2)
  • Real-world diagnostic biomarker efforts: NCT02616705 tests bile IgG4 as a biomarker to distinguish IgG4-SC from PSC/CCA/other strictures in a large prospective cohort (completed 2019; continued relevance for implementation). (NCT02616705 chunk 1)

Direct abstract-supported quotations (for key claims)

  • IgG4-SC definition/diagnostic challenge and need for consensus guidance: “IgG4‐related sclerosing cholangitis (IgG4‐SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4‐related disease.” (kamisawa2019clinicalpracticeguidelines pages 2-4)
  • HISORt-based diagnostic concept and relapse: “Diagnosis is challenging due to the absence of pathognomonic findings but can be achieved using the HISORt criteria (histology, imaging, serology, other organ involvement, and response to immunosuppressive therapy).” (herta2025managementofigg4related pages 1-2)
  • Steroid response but relapse: “IgG4-SC often has a good response to initial steroid therapy, but a high relapse rate during follow-up.” (majumder2018rituximabmaintenancetherapy pages 1-2)

Limitations of this evidence package

  • Formal ontology identifiers (MONDO/MeSH/Orphanet/ICD) and many ontology mappings (HPO/GO/CL/UBERON/MAXO) were not explicitly provided in retrieved full-text sources; ontology suggestions are therefore limited to widely used terms and should be validated against the relevant ontology releases.
  • Several key 2023–2024 primary papers/guidelines relevant to IgG4-SC may be unobtainable in this run (e.g., certain systematic reviews/meta-analyses and some 2023 nationwide relapse/cancer-risk studies), so some “latest” claims (e.g., anti-CD19 trial outcomes in IgG4-RD) are discussed only at a high level.

References

  1. (herta2025managementofigg4related pages 1-2): Toni Herta, Maik Schröder, Dominik Geisel, Cornelius Engelmann, and Frank Tacke. Management of igg4-related cholangitis: diagnosis, therapy, and long-term surveillance. Gastroenterology Report, Apr 2025. URL: https://doi.org/10.1093/gastro/goaf032, doi:10.1093/gastro/goaf032. This article has 1 citations and is from a peer-reviewed journal.

  2. (ali2020thelongtermoutcomes pages 1-2): Ahmad Hassan Ali, Yan Bi, Jorge D. Machicado, Sushil Garg, Ryan J. Lennon, Lizhi Zhang, Naoki Takahashi, Elizabeth J. Carey, Keith D. Lindor, J. Gage Buness, James H. Tabibian, and Suresh T. Chari. The long-term outcomes of patients with immunoglobulin g4-related sclerosing cholangitis: the mayo clinic experience. Journal of Gastroenterology, 55:1087-1097, Aug 2020. URL: https://doi.org/10.1007/s00535-020-01714-7, doi:10.1007/s00535-020-01714-7. This article has 37 citations and is from a domain leading peer-reviewed journal.

  3. (majumder2018rituximabmaintenancetherapy pages 1-2): Shounak Majumder, Sonmoon Mohapatra, Ryan J. Lennon, Guilherme Piovezani Ramos, Neil Postier, Ferga C. Gleeson, Michael J. Levy, Randall K. Pearson, Bret T. Petersen, Santhi Swaroop Vege, Suresh T. Chari, Mark D. Topazian, and Thomas E. Witzig. Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin g4-related disease. Clinical Gastroenterology and Hepatology, 16:1947-1953, Dec 2018. URL: https://doi.org/10.1016/j.cgh.2018.02.049, doi:10.1016/j.cgh.2018.02.049. This article has 101 citations and is from a domain leading peer-reviewed journal.

  4. (kamisawa2019clinicalpracticeguidelines pages 6-7): Terumi Kamisawa, Takahiro Nakazawa, Susumu Tazuma, Yoh Zen, Atsushi Tanaka, Hirotaka Ohara, Takashi Muraki, Kazuo Inui, Dai Inoue, Takayoshi Nishino, Itaru Naitoh, Takao Itoi, Kenji Notohara, Atsushi Kanno, Kensuke Kubota, Kenji Hirano, Hiroyuki Isayama, Kyoko Shimizu, Toshio Tsuyuguchi, Tooru Shimosegawa, Shigeyuki Kawa, Tsutomu Chiba, Kazuichi Okazaki, Hajime Takikawa, Wataru Kimura, Michiaki Unno, and Masahiro Yoshida. Clinical practice guidelines for igg4‐related sclerosing cholangitis. Journal of Hepato-Biliary-Pancreatic Sciences, 26:9-42, Jan 2019. URL: https://doi.org/10.1002/jhbp.596, doi:10.1002/jhbp.596. This article has 225 citations and is from a peer-reviewed journal.

  5. (ali2020thelongtermoutcomes pages 2-4): Ahmad Hassan Ali, Yan Bi, Jorge D. Machicado, Sushil Garg, Ryan J. Lennon, Lizhi Zhang, Naoki Takahashi, Elizabeth J. Carey, Keith D. Lindor, J. Gage Buness, James H. Tabibian, and Suresh T. Chari. The long-term outcomes of patients with immunoglobulin g4-related sclerosing cholangitis: the mayo clinic experience. Journal of Gastroenterology, 55:1087-1097, Aug 2020. URL: https://doi.org/10.1007/s00535-020-01714-7, doi:10.1007/s00535-020-01714-7. This article has 37 citations and is from a domain leading peer-reviewed journal.

  6. (smit2016newthoughtson pages 6-8): Wouter L. Smit, Emma L. Culver, and Roger W. Chapman. New thoughts on immunoglobulin g4-related sclerosing cholangitis. Clinics in liver disease, 20 1:47-65, Feb 2016. URL: https://doi.org/10.1016/j.cld.2015.08.004, doi:10.1016/j.cld.2015.08.004. This article has 21 citations and is from a peer-reviewed journal.

  7. (ren2026igg4relatedsclerosingcholangitis pages 2-3): Xiangxiang Ren, Xiaoshi Jin, Litao Liu, and Meng Zhang. Igg4-related sclerosing cholangitis: navigating diagnostic dilemmas and the challenge of relapse. Frontiers in Medicine, 13:1732637, Feb 2026. URL: https://doi.org/10.3389/fmed.2026.1732637, doi:10.3389/fmed.2026.1732637. This article has 0 citations.

  8. (naitoh2026multicentervalidationstudy pages 2-2): Itaru Naitoh, Takahiro Nakazawa, Kensuke Kubota, Takayoshi Nishino, Akira Nakamura, Dai Inoue, Takanori Sano, Kazuhiro Kikuta, Yusuke Kurita, Kazuro Chiba, Tsukasa Ikeura, Hiroyuki Matsubayashi, Takuya Ishikawa, Masaki Kuwatani, Terumi Kamisawa, Ichiro Yasuda, Mitsuhiro Kawano, and Atsushi Masamune. Multicenter validation study of the clinical diagnostic criteria for igg4 ‐related sclerosing cholangitis 2020 in japan. Journal of Hepato-Biliary-Pancreatic Sciences, 33:294-303, Jan 2026. URL: https://doi.org/10.1002/jhbp.70056, doi:10.1002/jhbp.70056. This article has 3 citations and is from a peer-reviewed journal.

  9. (naitoh2026multicentervalidationstudy pages 1-2): Itaru Naitoh, Takahiro Nakazawa, Kensuke Kubota, Takayoshi Nishino, Akira Nakamura, Dai Inoue, Takanori Sano, Kazuhiro Kikuta, Yusuke Kurita, Kazuro Chiba, Tsukasa Ikeura, Hiroyuki Matsubayashi, Takuya Ishikawa, Masaki Kuwatani, Terumi Kamisawa, Ichiro Yasuda, Mitsuhiro Kawano, and Atsushi Masamune. Multicenter validation study of the clinical diagnostic criteria for igg4 ‐related sclerosing cholangitis 2020 in japan. Journal of Hepato-Biliary-Pancreatic Sciences, 33:294-303, Jan 2026. URL: https://doi.org/10.1002/jhbp.70056, doi:10.1002/jhbp.70056. This article has 3 citations and is from a peer-reviewed journal.

  10. (kamisawa2019clinicalpracticeguidelines pages 2-4): Terumi Kamisawa, Takahiro Nakazawa, Susumu Tazuma, Yoh Zen, Atsushi Tanaka, Hirotaka Ohara, Takashi Muraki, Kazuo Inui, Dai Inoue, Takayoshi Nishino, Itaru Naitoh, Takao Itoi, Kenji Notohara, Atsushi Kanno, Kensuke Kubota, Kenji Hirano, Hiroyuki Isayama, Kyoko Shimizu, Toshio Tsuyuguchi, Tooru Shimosegawa, Shigeyuki Kawa, Tsutomu Chiba, Kazuichi Okazaki, Hajime Takikawa, Wataru Kimura, Michiaki Unno, and Masahiro Yoshida. Clinical practice guidelines for igg4‐related sclerosing cholangitis. Journal of Hepato-Biliary-Pancreatic Sciences, 26:9-42, Jan 2019. URL: https://doi.org/10.1002/jhbp.596, doi:10.1002/jhbp.596. This article has 225 citations and is from a peer-reviewed journal.

  11. (ali2020thelongtermoutcomes pages 7-8): Ahmad Hassan Ali, Yan Bi, Jorge D. Machicado, Sushil Garg, Ryan J. Lennon, Lizhi Zhang, Naoki Takahashi, Elizabeth J. Carey, Keith D. Lindor, J. Gage Buness, James H. Tabibian, and Suresh T. Chari. The long-term outcomes of patients with immunoglobulin g4-related sclerosing cholangitis: the mayo clinic experience. Journal of Gastroenterology, 55:1087-1097, Aug 2020. URL: https://doi.org/10.1007/s00535-020-01714-7, doi:10.1007/s00535-020-01714-7. This article has 37 citations and is from a domain leading peer-reviewed journal.

  12. (hegade2019diagnosisandmanagement pages 5-6): Vinod S Hegade, Maria B Sheridan, and Matthew T Huggett. Diagnosis and management of igg4-related disease. Frontline Gastroenterology, 10:275-283, Oct 2019. URL: https://doi.org/10.1136/flgastro-2018-101001, doi:10.1136/flgastro-2018-101001. This article has 46 citations and is from a peer-reviewed journal.

  13. (hegade2019diagnosisandmanagement pages 4-5): Vinod S Hegade, Maria B Sheridan, and Matthew T Huggett. Diagnosis and management of igg4-related disease. Frontline Gastroenterology, 10:275-283, Oct 2019. URL: https://doi.org/10.1136/flgastro-2018-101001, doi:10.1136/flgastro-2018-101001. This article has 46 citations and is from a peer-reviewed journal.

  14. (miyazawa2020managementofbiliary pages 1-2): Masaki Miyazawa, Hajime Takatori, Kazunori Kawaguchi, Kazuya Kitamura, Kuniaki Arai, Koichiro Matsuda, Takeshi Urabe, Katsuhisa Inamura, Takuya Komura, Hideki Mizuno, Uichiro Fuchizaki, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, and Shuichi Kaneko. Management of biliary stricture in patients with igg4-related sclerosing cholangitis. PLoS ONE, 15:e0232089, Apr 2020. URL: https://doi.org/10.1371/journal.pone.0232089, doi:10.1371/journal.pone.0232089. This article has 18 citations and is from a peer-reviewed journal.

  15. (beuers2025igg4relatedcholangitis pages 1-3): Ulrich Beuers and David C. Trampert. Igg4-related cholangitis. Seminars in Liver Disease, May 2025. URL: https://doi.org/10.1055/a-2588-3875, doi:10.1055/a-2588-3875. This article has 1 citations and is from a peer-reviewed journal.

  16. (hegade2019diagnosisandmanagement pages 1-2): Vinod S Hegade, Maria B Sheridan, and Matthew T Huggett. Diagnosis and management of igg4-related disease. Frontline Gastroenterology, 10:275-283, Oct 2019. URL: https://doi.org/10.1136/flgastro-2018-101001, doi:10.1136/flgastro-2018-101001. This article has 46 citations and is from a peer-reviewed journal.

  17. (cargill2017igg4relatedsclerosingcholangitis pages 2-4): T. Cargill, E. Culver, and R. Chapman. Igg4-related sclerosing cholangitis. Biliary Disease, pages 243-261, Jan 2017. URL: https://doi.org/10.1007/978-3-319-50168-0_12, doi:10.1007/978-3-319-50168-0_12. This article has 29 citations.

  18. (NCT02616705 chunk 1): Lewis R. Roberts. Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis. Mayo Clinic. 2015. ClinicalTrials.gov Identifier: NCT02616705

  19. (smit2016newthoughtson pages 12-14): Wouter L. Smit, Emma L. Culver, and Roger W. Chapman. New thoughts on immunoglobulin g4-related sclerosing cholangitis. Clinics in liver disease, 20 1:47-65, Feb 2016. URL: https://doi.org/10.1016/j.cld.2015.08.004, doi:10.1016/j.cld.2015.08.004. This article has 21 citations and is from a peer-reviewed journal.

  20. (tanaka2019igg4relatedsclerosingcholangitis pages 1-2): Atsushi Tanaka. Igg4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut and Liver, 13:300-307, May 2019. URL: https://doi.org/10.5009/gnl18085, doi:10.5009/gnl18085. This article has 84 citations and is from a peer-reviewed journal.

  21. (noble2025epigeneticageacceleration pages 1-2): Alexandra Noble, Rodrigo Motta, Silvia Cabras, Belen Moron Flores, Jan Nowak, Aleksandra Glapa-Nowak, Alessandra Geremia, Jack Satsangi, and Emma Culver. Epigenetic age acceleration and methylation differences in igg4-related cholangitis and primary sclerosing cholangitis. Clinical Epigenetics, Jan 2025. URL: https://doi.org/10.1186/s13148-024-01803-x, doi:10.1186/s13148-024-01803-x. This article has 2 citations and is from a peer-reviewed journal.

  22. (berntsen2015associationbetweenhla pages 1-1): Natalie L. Berntsen, Olav Klingenberg, Brian D. Juran, Maria Benito de Valle, Björn Lindkvist, Konstantinos N. Lazaridis, Kirsten Muri Boberg, Tom H. Karlsen, and Johannes Roksund Hov. Association between hla haplotypes and increased serum levels of igg4 in patients with primary sclerosing cholangitis. Gastroenterology, 148 5:924-927.e2, May 2015. URL: https://doi.org/10.1053/j.gastro.2015.01.041, doi:10.1053/j.gastro.2015.01.041. This article has 59 citations and is from a highest quality peer-reviewed journal.

  23. (culver2016igg4relatedhepatobiliarydisease pages 7-8): Emma L. Culver and Roger W. Chapman. Igg4-related hepatobiliary disease: an overview. Nature Reviews Gastroenterology &Hepatology, 13:601-612, Oct 2016. URL: https://doi.org/10.1038/nrgastro.2016.132, doi:10.1038/nrgastro.2016.132. This article has 109 citations.

  24. (miyazawa2020managementofbiliary media 3f18bf73): Masaki Miyazawa, Hajime Takatori, Kazunori Kawaguchi, Kazuya Kitamura, Kuniaki Arai, Koichiro Matsuda, Takeshi Urabe, Katsuhisa Inamura, Takuya Komura, Hideki Mizuno, Uichiro Fuchizaki, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, and Shuichi Kaneko. Management of biliary stricture in patients with igg4-related sclerosing cholangitis. PLoS ONE, 15:e0232089, Apr 2020. URL: https://doi.org/10.1371/journal.pone.0232089, doi:10.1371/journal.pone.0232089. This article has 18 citations and is from a peer-reviewed journal.

  25. (miyazawa2020managementofbiliary media a80fe471): Masaki Miyazawa, Hajime Takatori, Kazunori Kawaguchi, Kazuya Kitamura, Kuniaki Arai, Koichiro Matsuda, Takeshi Urabe, Katsuhisa Inamura, Takuya Komura, Hideki Mizuno, Uichiro Fuchizaki, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, and Shuichi Kaneko. Management of biliary stricture in patients with igg4-related sclerosing cholangitis. PLoS ONE, 15:e0232089, Apr 2020. URL: https://doi.org/10.1371/journal.pone.0232089, doi:10.1371/journal.pone.0232089. This article has 18 citations and is from a peer-reviewed journal.

  26. (miyazawa2020managementofbiliary media 500893f9): Masaki Miyazawa, Hajime Takatori, Kazunori Kawaguchi, Kazuya Kitamura, Kuniaki Arai, Koichiro Matsuda, Takeshi Urabe, Katsuhisa Inamura, Takuya Komura, Hideki Mizuno, Uichiro Fuchizaki, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, and Shuichi Kaneko. Management of biliary stricture in patients with igg4-related sclerosing cholangitis. PLoS ONE, 15:e0232089, Apr 2020. URL: https://doi.org/10.1371/journal.pone.0232089, doi:10.1371/journal.pone.0232089. This article has 18 citations and is from a peer-reviewed journal.